REPORT ID 2699

United States Neurological Biomarkers Market Report 2019

Publish Date
2019
Pages
111
Format
Electronic (PDF)

In this report, the United States Neurological Biomarkers market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Neurological Biomarkers in these regions, from   2019 to 2025 (forecast).

United States Neurological Biomarkers market competition by top manufacturers/players, with Neurological Biomarkers sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Thermo Fisher Scientific (U.S.)
    Qiagen (Germany)
    Myriad RBM (U.S.)
    Proteome Sciences (UK)
    Banyan Biomarkers (U.S.)
    Cisbio Bioassays (U.S.)
    Abiant (U.S.)
    Acumen Pharmaceuticals (U.S.)
    Proteosys (Germany)
    Alseres Pharmaceuticals (U.S.)
    Athena Diagnostics (U.S.)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Alzheimer's Disease
    Parkinson's Disease
    Autism Spectrum Disorder
    Multiple Sclerosis
    Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Genomics
    Proteomics
    Metabolomics
    Imaging
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Neurological Biomarkers Market  Report 2019
1 Neurological Biomarkers Overview
    1.1 Product Overview and Scope of Neurological Biomarkers
    1.2 Classification of Neurological Biomarkers by Product Category
        1.2.1 United States Neurological Biomarkers Market Size (Sales Volume) Comparison by Type ( 2014-2024)
        1.2.2 United States Neurological Biomarkers Market Size (Sales Volume) Market Share by Type (Product Category)  in 2018
        1.2.3 Alzheimer's Disease
        1.2.4 Parkinson's Disease
        1.2.5 Autism Spectrum Disorder
        1.2.6 Multiple Sclerosis
        1.2.7 Other
    1.3 United States Neurological Biomarkers Market by Application/End Users
        1.3.1 United States Neurological Biomarkers Market Size (Consumption) and Market Share Comparison by Application ( 2014-2024)
        1.3.2 Genomics
        1.3.3 Proteomics
        1.3.4 Metabolomics
        1.3.5 Imaging
        1.3.6 Other
    1.4 United States Neurological Biomarkers Market by Region
        1.4.1 United States Neurological Biomarkers Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 The West Neurological Biomarkers Status and Prospect ( 2014-2024)
        1.4.3 Southwest Neurological Biomarkers Status and Prospect ( 2014-2024)
        1.4.4 The Middle Atlantic Neurological Biomarkers Status and Prospect ( 2014-2024)
        1.4.5 New England Neurological Biomarkers Status and Prospect ( 2014-2024)
        1.4.6 The South Neurological Biomarkers Status and Prospect ( 2014-2024)
        1.4.7 The Midwest Neurological Biomarkers Status and Prospect ( 2014-2024)
    1.5 United States Market Size (Value and Volume) of Neurological Biomarkers ( 2014-2024)
        1.5.1 United States Neurological Biomarkers Sales and Growth Rate ( 2014-2024)
        1.5.2 United States Neurological Biomarkers Revenue and Growth Rate ( 2014-2024)

2 United States Neurological Biomarkers Market Competition by Players/Suppliers
    2.1 United States Neurological Biomarkers Sales and Market Share of Key Players/Suppliers ( 2014-2019)
    2.2 United States Neurological Biomarkers Revenue and Share by Players/Suppliers ( 2014-2019)
    2.3 United States Neurological Biomarkers Average Price by Players/Suppliers ( 2014-2019)
    2.4 United States Neurological Biomarkers Market Competitive Situation and Trends
        2.4.1 United States Neurological Biomarkers Market Concentration Rate
        2.4.2 United States Neurological Biomarkers Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Neurological Biomarkers Manufacturing Base Distribution, Sales Area, Product Type

3 United States Neurological Biomarkers Sales (Volume) and Revenue (Value) by Region ( 2014-2019)
    3.1 United States Neurological Biomarkers Sales and Market Share by Region ( 2014-2019)
    3.2 United States Neurological Biomarkers Revenue and Market Share by Region ( 2014-2019)
    3.3 United States Neurological Biomarkers Price by Region ( 2014-2019)

4 United States Neurological Biomarkers Sales (Volume) and Revenue (Value) by Type (Product Category) ( 2014-2019)
    4.1 United States Neurological Biomarkers Sales and Market Share by Type (Product Category) ( 2014-2019)
    4.2 United States Neurological Biomarkers Revenue and Market Share by Type ( 2014-2019)
    4.3 United States Neurological Biomarkers Price by Type ( 2014-2019)
    4.4 United States Neurological Biomarkers Sales Growth Rate by Type ( 2014-2019)

5 United States Neurological Biomarkers Sales (Volume) by Application ( 2014-2019)
    5.1 United States Neurological Biomarkers Sales and Market Share by Application ( 2014-2019)
    5.2 United States Neurological Biomarkers Sales Growth Rate by Application ( 2014-2019)
    5.3 Market Drivers and Opportunities

6  United States Neurological Biomarkers Players/Suppliers Profiles and Sales Data
    6.1 Thermo Fisher Scientific (U.S.)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Neurological Biomarkers Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Thermo Fisher Scientific (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Qiagen (Germany)
        6.2.2 Neurological Biomarkers Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Qiagen (Germany) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Myriad RBM (U.S.)
        6.3.2 Neurological Biomarkers Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Myriad RBM (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Proteome Sciences (UK)
        6.4.2 Neurological Biomarkers Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Proteome Sciences (UK) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Banyan Biomarkers (U.S.)
        6.5.2 Neurological Biomarkers Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Banyan Biomarkers (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Cisbio Bioassays (U.S.)
        6.6.2 Neurological Biomarkers Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Cisbio Bioassays (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Abiant (U.S.)
        6.7.2 Neurological Biomarkers Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Abiant (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Acumen Pharmaceuticals (U.S.)
        6.8.2 Neurological Biomarkers Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Acumen Pharmaceuticals (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Proteosys (Germany)
        6.9.2 Neurological Biomarkers Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Proteosys (Germany) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Alseres Pharmaceuticals (U.S.)
        6.10.2 Neurological Biomarkers Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Alseres Pharmaceuticals (U.S.) Neurological Biomarkers Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Athena Diagnostics (U.S.)

7 Neurological Biomarkers Manufacturing Cost Analysis
    7.1 Neurological Biomarkers Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Neurological Biomarkers

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Neurological Biomarkers Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Neurological Biomarkers Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Neurological Biomarkers Market Size (Value and Volume) Forecast ( 2019-2025)
    11.1 United States Neurological Biomarkers Sales Volume, Revenue Forecast ( 2019-2025)
    11.2 United States Neurological Biomarkers Sales Volume Forecast by Type ( 2019-2025)
    11.3 United States Neurological Biomarkers Sales Volume Forecast by Application ( 2019-2025)
    11.4 United States Neurological Biomarkers Sales Volume Forecast by Region ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer